Lyell Immunopharma

LYELNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$273.232 M

$11.15 +2.01%

Close of 22 Sept 2026

Revenue

$36.0K

#3616 by revenue

Earnings

-$274.4M

Loss-making

Shares outstanding

24,505,141

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#242Pyxis OncologyPYXS$279.8M
#243AC ImmuneACIU$277.8M
#244Lyell ImmunopharmaLYEL$273.2M
#245Sionna TherapeuticsSION$272.2M
#246Akebia TherapeuticsAKBA$271.6M

What if Lyell Immunopharma were worth as much as…

Open the what-if tool →

Gold $30.2T

$1,233,781

Per share 110,653× higher

Bitcoin $1.74T

$71,073.05

Per share 6,374× higher

Nvidia $5.52T

$225,086.12

Per share 20,187× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Lyell Immunopharma are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.